NAD+ for Performance Athletes: Recovery and Output Data

NAD+ has acquired the status of a default recovery and performance therapy in some athletic communities. The marketing around it ranges from the credible (mitochondrial-function support, recovery quality) to the overstated (acute power output gains, "running faster" claims). This post is the version of NAD+-for-athletes that does not oversell the data — what is actually known, what is plausibly true, what the practical protocol looks like in trained athletes, and where the prescribed model differs from the cash-pay IV-drip market.

The audience for this post is performance-oriented athletes — endurance, strength, mixed-modality — who are weighing NAD+ as part of a recovery or longevity strategy, and who want the answer to be calibrated rather than enthusiastic.

What NAD+ is and why athletes care

NAD+ — nicotinamide adenine dinucleotide — is a metabolic cofactor present in every living cell. It is a substrate for oxidative phosphorylation in mitochondria, where it cycles between NAD+ and NADH as electrons move through the respiratory chain. It is also a substrate for several non-energetic processes, including DNA repair (via PARP enzymes) and gene-expression regulation (via sirtuin enzymes).

NAD+ levels decline with age. They also fluctuate with metabolic stress, including the stress of high training loads. The relevance of this for athletes is that several recovery-relevant biological processes — mitochondrial repair and biogenesis, DNA-damage repair from reactive-oxygen-species-mediated stress, and the inflammatory regulation associated with sirtuin signaling — are NAD+-dependent.

The mechanistic argument for NAD+ in athletes is therefore:

1. Training loads deplete NAD+ in stressed tissue, particularly skeletal muscle.
2. Recovery-relevant cellular processes are NAD+-dependent.
3. Restoring NAD+ levels through supplementation may shorten the time-to-baseline for these processes.

This argument is biologically reasonable. The translation to actual measurable performance and recovery improvements in trained athletes is where the data gets more nuanced.

What the data actually shows

The NAD+ literature in athletes is smaller than the longevity-oriented literature, and most of the available studies are short-duration and modestly sized. The endpoints that have been studied most consistently are:

Mitochondrial-function markers. Studies measuring mitochondrial respiration (typically via permeabilized muscle fiber preparations or specialized non-invasive techniques) have generally found that NAD+ supplementation, including via oral precursors and parenteral NAD+, produces measurable improvements in mitochondrial efficiency. The effect sizes are modest but consistent.

Inflammatory markers. CRP, IL-6, and related markers have shown reductions in some studies, particularly in older or higher-training-volume populations. The mechanism is plausibly through sirtuin-mediated regulation of inflammatory transcription factors.

Subjective fatigue and recovery quality. Patient-reported outcomes — ratings of perceived fatigue, sleep quality, training-day-after recovery — have improved in most clinical and observational reports. These endpoints are subjective by construction and cannot stand alone, but they are consistent.

Direct performance endpoints. Here the data is more variable. Power output, VO2max, and time-to-exhaustion at fixed workload have not consistently improved across trained-athlete studies. Some studies have shown small effects; others have shown no effect; meta-analytic synthesis is limited by heterogeneity. The honest characterization is that NAD+ is not reliably ergogenic in trained athletes in the way a true performance-enhancing intervention would be.

Training-load tolerance. Some observational and small interventional reports suggest athletes on NAD+ protocols can sustain higher training loads with the same or lower subjective recovery cost. This is mechanistically plausible and clinically interesting but the studies that exist are not large enough to generalize confidently.

The summary version: NAD+ has the better evidence in athletes for recovery, mitochondrial function, and inflammation. It has weaker evidence for direct acute performance enhancement. Anyone characterizing it primarily as a performance booster is reading the data more enthusiastically than is warranted.

Why the IV-drip marketing overshoots

A category of cash-pay clinics offer NAD+ as a wellness IV-drip service, often at high prices, sometimes with explicit performance claims. The marketing typically does several things that the data does not support:

• Frames NAD+ as an acute performance intervention. The data on acute (same-day or same-week) performance is weak. The recovery-and-cumulative-effect framing is much better supported.
• Implies effects on outcomes (race results, PRs) that have not been studied. NAD+ on competition outcomes in elite athletes is not a body of evidence; it is at most a hypothesis.
• Treats IV as the only or best route. IV NAD+ is one of several legitimate routes. Subcutaneous and intramuscular routes are well-tolerated, less expensive, easier to administer on a regular cadence, and supported by the same underlying pharmacology. There is no robust head-to-head data establishing IV superiority over SQ for recovery-focused use.
• Operates outside a prescribed-medication framework. Cash-pay drip clinics are wellness-category services in most cases. The substrate may be the same, but there is no medical eligibility review, prescribing context, or structured follow-up.

The prescribed model is different. NAD+ through a licensed prescriber is a regulated medical service with documented dosing, indication, follow-up, and a clinical eligibility check that screens for contraindications. The cost is typically lower per unit. The substrate is the same molecule. The wrapper around it is different.

What a prescribed NAD+ protocol for athletes looks like

For athletes whose goal is recovery support, mitochondrial function, and tolerance of training load, the prescribed protocols TelePeptide uses share a common shape:

Loading phase. A higher-frequency dosing window, typically the first two to four weeks, designed to bring tissue NAD+ to a stable elevated baseline. Doses are titrated to the patient's training context and tolerability.

Maintenance phase. A lower-frequency cadence, typically once or twice weekly, that maintains the elevated baseline without unnecessary cost or administration burden. The maintenance phase is where most of the long-run benefit accrues.

Periodization around training. For athletes with a structured periodization model (a build phase, a peak, a recovery block), NAD+ dosing can be aligned with training stress. Higher-intensity training blocks pair with maintained or modestly elevated NAD+ dosing; recovery weeks pair with reduced dosing or hold.

Tracking. Subjective fatigue, sleep quality, training-day-after recovery, and where appropriate objective markers (heart-rate variability, training-load tolerance metrics from a wearable) are tracked across the protocol. The point of tracking is not to prove the protocol works for the patient but to make the question answerable: if the metrics do not move, the protocol is not justifying its cost and should be reconsidered.

Combination with the rest of the recovery framework. NAD+ does not replace sleep, nutrition, periodization, or other recovery fundamentals. It augments. The patients who get the most out of NAD+ are typically the ones who already have the rest of the framework in place.

Routes of administration

NAD+ can be administered in several ways. The differences matter:

• Intravenous. Direct administration into circulation, with rapid availability. Most expensive and most administration-intensive route. Typically used in clinical settings or by patients who want infrequent high-dose administrations rather than a regular self-administered cadence.
• Subcutaneous. Injection into subcutaneous tissue, typically self-administered. Excellent practicality for ongoing protocols. Tolerability can be improved by site rotation and slow administration.
• Intramuscular. Injection into muscle tissue. Less common than SQ for ongoing protocols but used in some prescribing contexts.
• Oral NAD+. Oral NAD+ itself is not bioavailable in any meaningful sense; the molecule is degraded in the gastrointestinal tract.
• Oral NAD+ precursors (NMN, NR). These raise tissue NAD+ via a different pharmacokinetic pathway. They are not banned, are widely available, and have their own data. They are not interchangeable with parenteral NAD+, and the choice between them is a separate discussion.

For most athlete patients on TelePeptide protocols, subcutaneous or intramuscular self-administration is the default. The cadence is regular, the cost is reasonable, and the practicality supports adherence.

WADA and competition status

NAD+ is not currently on the World Anti-Doping Agency Prohibited List. It is a metabolic cofactor produced endogenously and supplementation does not fall into the categories that WADA prohibits.

A few important caveats:

1. The list updates annually. Athletes subject to testing should confirm status before each competition cycle.
2. Sport-specific governing bodies sometimes add restrictions. WADA is the baseline; individual federations may add to it.
3. NAD+ precursors (NMN, NR) are also not prohibited as of the current list, but the same caveats apply.

For athletes who require explicit clearance, written confirmation from the relevant governing body is the right standard, not the marketing claims of a clinic.

Who is appropriate for NAD+

NAD+ is not a default supplement. The patients who benefit most clearly from prescribed NAD+ in the athletic context are typically:

• High-volume training athletes with sustained recovery demand
• Older athletes (40+) experiencing the natural decline in endogenous NAD+
• Athletes with a significant training-load history who report cumulative fatigue
• Patients with documented mitochondrial-function concerns

Patients for whom NAD+ is not a clear fit:

• Athletes with low to moderate training volume who do not have meaningful recovery deficits
• Patients with active malignancy where NAD+ supplementation may be contraindicated
• Patients without a structured training context where the effects could be tracked

The prescribing review covers these. NAD+ is not the right intervention for every athlete, and a responsible prescriber will say so when it is not.

Cost and access

Prescribed NAD+ through TelePeptide is meaningfully less expensive than equivalent IV-drip clinic services for the same molecule. The cost difference reflects two things: the route (subcutaneous self-administration is cheaper than clinic-administered IV), and the prescribing model (licensed pharmacy supply is more cost-effective than wellness-clinic margins).

For athletes, the relevant comparison is typically not "NAD+ versus no NAD+" but "NAD+ through which channel." The prescribed channel is the right answer for almost every case where the goal is regular ongoing recovery support rather than occasional acute administration.

Bottom line

NAD+ for athletes has a real but modest evidence base centered on recovery, mitochondrial function, and inflammation rather than acute performance. The right framing is as a recovery and longevity-adjacent therapy, not a performance booster. The prescribed model — through a licensed prescriber, with eligibility review and structured follow-up — is materially different from the cash-pay IV-drip market and is the better channel for ongoing protocols.

For athletes weighing it, the question is not whether NAD+ "works" in some absolute sense but whether it produces measurable improvements in your own metrics over a defined trial period, at a cost that is justified by those improvements. The prescribed model is built to make that question answerable.